News

Kelsey Roelofs, MD, shares some useful tips for identifying and diagnosing thyroid eye disease for attendees of the 18th Annual Controversies in Modern Eye Care symposium.

James A. Katz, MD, discussed evolving treatments for Demodex blepharitis, highlighting traditional methods like tea tree oil and microblepharoexfoliation as well as a newer FDA-approved therapy, and emphasizing the need to examine the upper eyelid carefully to diagnose the condition.

The 18th annual Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and Arjan Hura, MD, with the aim of discussing the latest advancements in eye care.

Hura highlighted some of the key takeaways from the Controversies in Modern Eye Care symposium where presenters and attendees shared their insights into the latest advancements in refractive surgery, retina care, and collaborative eye care.

Dr Richard Lindstrom speaks about the future of dry eye and shares pearls for young eye surgeons

The almost 474,000 participants in the study had been diagnosed with uveitis between January 1, 2015, and February 25, 2021 in South Korea.

The A-IOL aims to correct both near and distance eyesight, reduce reliance on glasses or contact lenses, have no glare or halos, and restore the eye’s ability to focus.

The diagnostic screening technology is able to diagnose diabetic retinopathy by using 1 image taken of each eye with over 99% imageability.

Kamuvudine-8, also known as K8, is administered to the back of the eye via a sustained released intravitreal implant.

The meeting kicks off with symposia and an opening keynote speech from Ed Yong

Despite recognition of lenticular glutathione’s importance in lens formation for decades, why it declines with age remains a mystery.

According to the company, a subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in 2 patients. Safety data from the first cohort of the LIGHTHOUSE study will be presented at the Retinal Cell and Gene Therapy Innovation Summit 2024 being held May 3, 2024, in Seattle.

The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction.

Joseph Izatt was a skilled researcher and inventor who played a foundational role in the development of optical coherence tomography.

Several presentations will provide research updates on various topics related to retinal vein occlusion (RVO).

Rick Lewis, chief medical officer of ViaLase, describes the company's nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.

Alcon was ordered to pay $34 million to Sight Sciences after a trial by jury.

More companies have released information on presentations related to their pipelines and new data at the ARVO 2024 conference.

As the annual ARVO conference draws closer, more companies have released information on presentations related to their pipeline and new data.

Joseph Izatt was a skilled researcher and inventor who played a foundational role in the development of optical coherence tomography.

The data will be presented in oral session at the 2024 American Society of Gene & Cell Therapy meeting May 7-11 in Baltimore, Maryland.

Researchers found the model demonstrated “near-perfect” detection capabilities.

The intent of this extension is to assess potentially greater durability compared to aflibercept and will increase the statistical power of the study.

Researchers examined disparities in service coverage of pediatric ophthalmologists and pediatric optometrists in relation to patient demographics to cast a light on at-risk populations and provide data for future decisions.

The tool shows disease progression and vision loss simulations for multiple diseases such as AMD, XLRP, and achromatopsia